ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

被引：1
|
作者：
Gomella, Leonard G.
Chi, Kim N.
de Bono, Johann S.
Fizazi, Karim
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pelhivanov, Nonko
Charnas, Robert
Todd, Mary B.
Montgomery, Bruce
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1963
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-18
引用
收藏
页码：E1091 / E1091
页数：1
相关论文
共 50 条
  • [1] Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).
    Fizazi, Karim
    Chi, Kim N.
    De Bono, Johann Sebastian
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pehlivanov, Nonko
    Charnas, Robert Louis
    Todd, Mary Beth
    Montgomery, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Long-term (LT) Exposure to low-dose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients
    Ryan, Charles J.
    Chi, Kim N.
    de Bono, Johann S.
    Fizazi, Karim
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pelhivanov, Nonko
    Charnas, Robert
    Todd, Mary B.
    Montgomery, Bruce
    [J]. BJU INTERNATIONAL, 2015, 116 : 15 - 15
  • [3] Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
    Fizazi, Karim
    Chi, Kim N.
    de Bono, Johann S.
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pelhivanov, Nonko
    Charnas, Robert
    Todd, Mary B.
    Montgomery, Bruce
    [J]. EUROPEAN UROLOGY, 2016, 70 (03) : 438 - 444
  • [4] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Posadas, Edwin M.
    Chit, Kim N.
    de Wit, Ronald
    de Jonge, Maja J. A.
    Attard, Gerhardt
    Friedlander, Terence
    Yu, Margaret
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene
    Gonzalez, Martha
    Trudel, Geralyn C.
    Chauhan, Vijay
    Saad, Fred
    [J]. CANCER RESEARCH, 2015, 75
  • [5] Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA plus P) for ≥ 4 years (yrs)
    Carles, J.
    Davis, I.
    De Bono, J. S.
    Fizazi, K.
    Gerritsen, W.
    Rathkopf, D. E.
    Ryan, C. J.
    Saad, F.
    Steuber, T.
    Wilding, G.
    Park, Y. C.
    Charnas, R.
    De Porre, P.
    Van Poppel, H.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Chi, K. N.
    Spratlin, J.
    Kollmannsberger, C.
    North, S.
    Pankras, C.
    Chien, C.
    Gonzalez, M.
    Pang, L.
    Yu, M. K.
    Tran, N. P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S697
  • [7] Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    Yu, Margaret K.
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene Connelly
    Gonzalez, Martha
    Trudel, Geralyn Carol
    Chauhan, Vijay
    Jiao, Juhui James
    Saad, Fred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345